Search | German Center for Infection Research

Nov 2021

Lancet Infect Dis

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Autoren

Kremsner PG et al.

Jul 2021

J Public Aff

Critical prerequisites for Covid-19 vaccine acceleration: A developing economy perspective

Autoren

Hinson RE et al.

Vaccinated or recovered: Three exposures to spike protein lead to good immune protection

A new study from Munich shows that the immune system develops a high-quality antibody response after a total of three encounters with the viral spike protein of SARS-CoV-2. These antibodies can also

Characterisation of broadly neutralising antibodies against the hepatitis C virus

Despite improved methods of treatment, an infection with the hepatitis C virus still leads to approximately 400,000 deaths worldwide each year. The development of a vaccine is urgently required, but

Epstein-Barr virus: DZIF and Helmholtz Munich working on a vaccine

The Epstein-Barr virus (EBV) has been known for some time to play a part in a range of diseases. A current US study has now shown a close link between EBV and multiple sclerosis. DZIF scientists at

Sep 2014

J Infect Dis